Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Tobacco use is a global health care problem. Repetitive exposure to nicotine produces neuroadaptation resulting in nicotine dependence. Cigarette smoking is particularly addictive due to the repeated delivery of bolus doses of nicotine to the bloodstream. Although compulsive tobacco use is sustained by nicotine addiction, it is the toxic combustion products in tobacco smoke such as carbon monoxide and oxidant gases that adversely affect the cardiovascular system. Smoking cessation produces significant health benefits and is a very cost-effective intervention. Evidence that nicotine is the addictive component of tobacco provides the rationale for using nicotine replacement therapy to aid cessation. Nicotine replacement therapy doubles successful smoking cessation rates and evidence-based guidelines for the treatment of tobacco addiction recommend routine use of nicotine replacement therapy, particularly in heavily dependent smokers. Success rates of up to 40% can be achieved in specialist clinics. Despite early concerns regarding the safety of nicotine replacement therapy in smokers with heart disease, it is now clear that the health risks of using nicotine replacement therapy to assist such patients to stop, or significantly reduce, smoking far outweigh any treatment-related risks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A psychomotor stimulant theory of addiction.
Wise, R. A., & Bozarth, M. A. (1987) · Psychological Review · doi:10.1037/0033-295x.94.4.469 · Cited by 2,747
Measuring nicotine dependence: A review of the Fagerstrom Tolerance Questionnaire
Fagerstrom, K. O., & Schneider, N. G. (1989) · Journal of Behavioral Medicine · doi:10.1007/bf00846549 · Cited by 1,598
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585 · cited 2×
“In one study, the combination of bupropion plus nicotine replacement therapy showed a trend towards higher smoking cessation rates than bupropion alone([48]).”
BackgroundMortality from tobacco in developed countries: indirect estimation from national vital statistics.
Peto, R., Boreham, J., Lopez, A. D., Thun, M., & Heath, C. (1992) · The Lancet · doi:10.1016/0140-6736(92)91600-d · Cited by 1,394
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131 · cited 2×
“The Second Joint Task Force of the ESC recommendations on prevention of coronary heart disease in clinical practice emphasize life-style factors such as healthy nutrition, physical activity, non-smoking or smoking cessation([3]).”
BackgroundResultRole of 5-HT in stress, anxiety, and depression
Graeff, F. G., Guimarães, F. S., De Andrade, T. G. C. S., & Deakin, J. F. W. (1996) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)02135-3 · Cited by 984
Nicotine replacement therapy for smoking cessation
Silagy, C., Lancaster, T., Stead, L., Mant, D., & Fowler, G. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000146.pub2 · Cited by 972
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
Corrigall, W. A., Franklin, K. B. J., Coen, K. M., & Clarke, P. B. S. (1992) · Psychopharmacology · doi:10.1007/bf02245149 · Cited by 829
Pharmacology of Nicotine: Addiction and Therapeutics
Benowitz, N. L. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.003121 · Cited by 589 · cited 2×
“Repetitive exposure to nicotine produces neuroadaptation([5,10]).”
BackgroundSelf-citationBenowitz, N. L., & Gourlay, S. G. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00079-x · Cited by 529 · cited 1×
“Cigarette smoke contains a variety of chemicals that may adversely affect the cardiovascular system([9]).”
Background
Cited by
Prepared by: British Cardiac Society, B. H. S. (2005) · Heart · doi:10.1136/hrt.2005.079988 · Cited by 1,216
(2001) · European Heart Journal · doi:10.1053/euhj.2001.2610 · Cited by 893
Kotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., & Keil, U. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60330-5 · Cited by 833
Wood, D. A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04235-5 · Cited by 761
De Backer, G., Ambrosioni, E., Broch-Johnsen, K., Brotons, C., Cifkova, R., Dallongeville, J., Ebrahim, S., Faergeman, O., Graham, I., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention and Rehabilitation · doi:10.1097/00149831-200312001-00001 · Cited by 274
Interventions to reduce harm from continued tobacco use
Lindson-Hawley, N., Hartmann-Boyce, J., Fanshawe, T. R., Begh, R., Farley, A., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005231.pub3 · Cited by 273
Chaudhri, N., Caggiula, A. R., Donny, E. C., Palmatier, M. I., Liu, X., & Sved, A. F. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0178-1 · Cited by 271
“However, as a primary reinforcer, nicotine can establish associated neutral stimuli as conditioned reinforcers (Rose and Levin 1991; Balfour et al. 2000; Balfour 2004).”
InfluentialKotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., Reiner, Ž., Keil, U., & EUROASPIRE Study Group (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283383f30 · Cited by 238
Dhalwani, N. N., Szatkowski, L., Coleman, T., Fiaschi, L., & Tata, L. J. (2019) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty019 · Cited by 15
Metadata
- Authors
- Balfour, D.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-03-15
- Volume
- 21
- Issue
- 6
- Pages
- 438-445
- ISSN
- 0195-668X (ISSN-L)
- OpenAlex
- W2042717749
- Cited by
- 83
- References
- 14
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.